क्यूआर कोड

Intrinsic resistance to RAS inhibitors is driven by dysregulation of KRAS degradation

Abstract Activating mutations in KRAS occur in approximately 30% of lung adenocarcinomas. Despite advances in RAS-targeted therapies, intrinsic resistance limits their long-term efficacy. Here, we identify elevated levels of wild-type KRAS (WT-KRAS) protein as a key driver of intrinsic resistance in...

पूर्ण विवरण

में बचाया:
मुख्य लेखकों: Tonci Ivanisevic, Yan Ma, Emiel Van Boxel, Wout Magits, Benoit Lechat, Zeynep Koçberber, Phillipp Willnow, Sarah-Maria Fendt, Greetje Vande Velde, Raj Sewduth, Anna A Sablina
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: Nature Portfolio 2025-12-01
श्रृंखला:Nature Communications
ऑनलाइन पहुंच:https://doi.org/10.1038/s41467-025-67109-5
टैग: टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन